Table 4.
Contingency table quantifying the percentage change in HbA1c after 3 months of exenatide therapy from baseline against the proportion of participants who went on to respond and not to respond to exenatide by 6 months.
| Number of responders and nonresponders | P value | |||
|---|---|---|---|---|
| Responders | Nonresponders | |||
| Difference in HbA1c after 3 months of exenatide therapy compared to baseline HbA1c (%) | x > 5 | 0 | 10 | 0.0001 |
| 0 < x ≤ 5 | 2 | 6 | 0.13 | |
| 0 | 2 | 3 | 0.65 | |
| −5 ≤ x < 0 | 4 | 10 | 0.041 | |
| −10 ≤ x < −5 | 7 | 9 | 0.29 | |
| −15 ≤ x < −10 | 7 | 6 | 0.85 | |
| −20 ≤ x < −15 | 13 | 3 | 0.033 | |
| −25 ≤ x < −20 | 11 | 2 | 0.037 | |
| −25 < x | 17 | 0 | 0.0001 | |
x denotes the percentage difference. A reduction in HbA1c from baseline after 3 months of exenatide therapy is indicated by a − value. HbA1c: glycated haemoglobin.